Participants of pioneering CRISPR gene editing trial see vision improve

• EDIT-101, a CRISPR-based treatment, demonstrated improvement in 79% of participants with inherited retinal degeneration.
• The treatment targeted a mutation in the CEP290 gene associated with Leber Congenital Amaurosis Type 10.
• Safety was confirmed, with no serious adverse events reported among the 14 participants.
• Visual acuity and quality of life showed clinically meaningful improvement.
• Further research is needed to optimize dosing and explore treatment effects across different age groups.